A TWO-YEAR STUDY OF CANCEROGENIC POTENTIAL OF THE NEW OPIOID RECEPTOR ANTAGONIST ONDELOPRAN IN RATS

Opioid receptor antagonists are widely used for the treatment of alcohol dependence. Currently, original drug Odelepran (INN: ondelopran) with a unique binding profi le to all three types of human opioid receptors (μ, κ, δ) is being developed by R-Pharm.

Aim of the study. To investigate a cancerogenic potential of the new opioid receptor antagonist ondelopran in a twoyear study in rats

Materials and methods. The study cancerogenic potencial was performed in male and female Wistar rats at the age of 8–10 weeks at the start of experiment. All animals were allocated to 8 groups. Each group consisted of 50 animals of each sex. Test item (ondelopran fi lm-coated tablets, 125 mg), was administered to the animals intragastrically as a tablets suspension in 1% starch solution daily, 5 days a week for 24 months in two doses: 10 mg/kg (equivalent therapeutic dose for humans) and 100 mg/kg. Animals of control groups were administered with placebo and vehicle (1% starch solution). Clinical observation and examination of animals were conducted weekly to detect any signs of intoxication; dynamics of the body weight and registration of animal deaths were also assessed. To assess the rate of the pathological changes, the macro- and microscopic examination of inner organs and neoplasms was conducted.

Results. During the study the mortality rates did not diff er between the groups. Clinical signs ts.and symptoms of intoxication upon administration of the tested item and placebo were not observed. Neoplasms were found in the organs of all groups of animals. More than 30 variants of neoplasms were identifi ed upon pathomorphological examination. The identifi ed tumors are typical for rats and considered as spontaneous age-related pathology. There was no statistically signifi cant diff erences between groups in the total incidence of tumors.

Conclusion. To conclude the above said, the test item of the ondelopran fi lm-coated tablets, 125 mg have no carcinogenic properties.

1. Ivanets NN, Anokhina IP, Vinnikova MA. Mul'titsentrovoe klinicheskoe issledovanie prolongirovannoi formy blokatora naltreksona — «prodetokson» dlya lecheniya bol'nykh s opiatnoi zavisimost'yu. Novye lekarstvennye preparaty. 2006;2:11-24. (In Russian).

2. Ivanets NN, Vinnikova MA. The experience of usage of vivitrol (injections of long-acting naltrexone) in foreign practice. Kazan Medical Journal. 2009;90 (5):744-752. (In Russian).

3. Shagiakhmedov FSh, Grishin SA, Anokhin PK, Shamakina IYu. Fundamentals of the therapeutic effect of opioid antagonists in alcohol addiction treatment: the role of kopioid receptors. Voprosy narkologii. 2015;4:73-96. (In Russian).

4. Emmerson PJ, McKinzie JH, Surface PL, Suter TM, Mitch CH, Statnick MA. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists. European Journal of Pharmacology. Elsevier BV; 2004 Jun;494 (2-3):121-30. DOI: 10.1016/j.ejphar.2004.04.050

5. Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, et al. A Phase 2, Placebo-Controlled Study of the Opioid Receptor Antagonist LY2196044 for the Treatment of Alcohol Dependence.

6. Krupitsky E, Mukhametshina E, Samsonov M. A phase 3, multicenter randomized double blind placebo controlled study of the opioid receptor antagonist — Odelepran for the treatment of alcohol addiction. Int J Neuropsychopharmacol. 2016 Jun;19 (Suppl 1):10.

7. Bunyatyan ND, Vasil'ev AN, Verstakova OL, Zhuravleva MV, Lepakhin VK, Korobov NV, et al. Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv [Guidelines for pre-clinical research of drugs]. Edited by Mironov AN. Part 1. Moscow: "Grif i K" Publ.; 2012, 944 p. (In Russian).

8. Muzhikyan A, Makarova M, Gushin Y. Features histological processing of organs and tissues of laboratory animals. Mezhdunarodnyi Vestnik Veterinarii. 2014;2:103-109. (In Russian).

9. Gushchin Ya, Muzhikyan A. Effect of fixing liquids on microscopic structure of small laboratory animals. Mezhdunarodnyi Vestnik Veterinarii. 2014;3:88-95. (In Russian).

10. Deerberg F. Age-associated versus husbandry-related pathology of aging rats. Neurobiol Aging. 1991 Nov-Dec;12 (6):659-62.

11. Phillips PM, Jarema KA, Kurtz DM, MacPhaill RC. An observational assessment method for aging laboratory rats. J Am Assoc Lab Anim Sci. 2010 Nov;49 (6):792—9.

12. Spravochnik. Fiziologicheskie, biokhimicheskie i biometricheskie pokazateli normy eksperimental'nykh zhivotnykh [Physiological, biochemical and biometric parameters of the norm of experimental animals]. St. Petersburg: "LEMA" Publ.; 2013. (In Russian).

13. Anisimov VN. Carcinogenesis and aging, vol. 1/2. Boca Raton, FL: CRC Press; 1987.

14. Walsh K, Poteracki J. Spontaneous Neoplasms in Control Wistar Rats. Toxicological Sciences. Oxford University Press (OUP); 1994;22 (1):65-72. DOI: 10.1093/toxsci/22.1.65.

15. Ward JM. Background Data and Variations in Tumor Rates of Control Rats and Mice. Skin Painting Techniques and in vivo Carcinogenesis Bioassays. S. Karger AG; 1981: 241-58. DOI: 10.1159/000407263.

16. Suzuki H, Mohr U, Kimmerle G. Spontaneous endocrine tumors in Sprague-Dawley rats. J Cancer Res Clin Oncol. 1979 Oct; 95 (2):187—96. DOI: 10.1007/bf00401012.

17. Thompson SW, Huseby RA, Fox MR, Davis CL, Hunt RD. Spontaneous tumors in the Sprague-Dawley rat. J Natl Cancer Inst. 1961 Nov;27:1037—57.

18. Kaspareit-Rittinghausen J, Wiese K, Deerberg F, Nitsche B. Incidence and morphology of spontaneous thyroid tumours in different strains of rats. J Comp Pathol. 1990 May;102 (4):421-32.

19. Samuelson E. Analyses of Rat Tumor Models for DMBA-in- duced Fibrosarcoma and Spontaneous Endometrial Carcinoma. University of Gothenburg, Sweden. 2008.

20. Vollmer G. Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer. 2003 Mar;10 (1):23-42.

21. Anisimov V. N. Molecular and Physiological Mechanisms of Aging. Nauka. St. Petersburg; 2003.

22. Bomhard E, Rinke M. Frequency of spontaneous tumours in Wistar rats in 2-year studies. Exp Toxicol Pathol.